Bisphosphonate use in chronic kidney disease: Association with adynamic bone disease in a bone histology series

Blood Purification

Volumn 29, Issue 3, 2010, Pages 293-299

  Amerling, Richard ^a,c   Harbord, Nikolas B ^a,c   Pullman, James ^b,c   Feinfeld, Donald A ^a,c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alendronate; Bisphosphonates; Chronic kidney disease; Osteoid; Osteopenia; Osteoporosis; Renal diseases

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM PHOSPHATE; DOXYCYCLINE; PARATHYROID HORMONE; RISEDRONIC ACID; TETRACYCLINE;

ADULT; ADYNAMIC BONE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE MASS; BONE MINERALIZATION; BONE STRUCTURE; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; GLOMERULUS FILTRATION RATE; HISTOLOGY; HUMAN; HUMAN TISSUE; ILIAC CREST; MALE; OSSIFICATION; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE AND BONES; BONE DENSITY; BONE DISEASES; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPOROSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY;

EID: 74249085619     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276666     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention (CDC): Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56: 161-165.
2. Moe S, Drüeke T, Cunningham J, et al: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945- 1953.
3. Feinfeld DA, Sherwood LM: Parathyroid hormone and 1,25-(OH) 2 D 3 in chronic renal failure. Kidney Int 1988; 33: 1049-1058.
4. Osteoporosis Prevention, Diagnosis, and Therapy, NIH Consensus Statement, 2000, March 27-29 (http://www.ncbi.nlm.nih.gov/ b o okshe l f /br. fcgi?book=hsnihcdc& part= A20225).
5. WHO Definition of Osteoporosis.
6. Stafford RS, Drieling RL, Hersh AL: National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Meds 2004; 164: 1525-1530.
7. Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
8. Lasseter KC, Porras AG, Denker A, et al: Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Investig 2005; 25: 107-114.
9. Linnebur SA, Milchak JL: Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function. Am J Geriatr Pharmacother 2004; 2: 213-218.
10. Miller PD, Roux C, Boonen S, , et al: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20: 2105-2115.
11. Gipson D, Katz LA, Stehman-Breen C: Principles of dialysis: special issues in women. Semin Nephrol 1999; 19: 140-147.
12. Schmidt A, Luger A, Horl WH: Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant 2002; 17: 368-371.
13. Suzuki T, Nagai H, Yoshida H, et al: Appropriateness and limitations of bone mineral measurements by DXA (dual energy X-ray absorptiometry) in the elderly - comparison with X-ray findings. Nippon Koshu Eisei Zasshi 1995; 42: 385-397.
14. Jones G, Nguyen T, Sambrook PN, et al: A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol 1995; 22: 932-936.
15. Ensrud KE, Lui LY, Taylor BC, et al: Osteoporotic Fractures Research Group. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167: 133-139.
16. Nickolas TL, McMahon DJ, Shane E: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006; 17: 3223-3232.
17. Fried LF, Biggs ML, Shlipak MG: Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 2007; 18: 282-286.
18. Rodriguez Garcia M, Gomez Alonso C, Naves Diaz M, et al: Prevalence of vertebral fractures and aortic calcifications in hemodialysis patients: comparison with a population of the same age and sex. Nefrologia 2003; 23(suppl 2):106-111.
19. Rix M, Andreassen H, Eskildsen P, et al: Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084-1093.
20. Klawansky S, Komaroff E, Cavanaugh PF, et al: Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int 2003; 14: 570-576.
21. Hsu CY, Cummings SR, McCulloch CE, et al: Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int 2002; 61: 1814-1820.
22. Lobao R, Carvalho AB, Cuppari L, et al: High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol 2004; 62: 432-439.
23. Miller PD: Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005; 3: 5-12.
24. Schwarz C, Sulzbacher I, Oberbauer R: Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006; 36: 13-22.
25. Liberman UA, Weiss SR, Broll J, et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-1443.
26. Cummings SR, Black DM, Thompson DE, et al: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082.
27. Harris ST, Watts NB, Genant HK, et al: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-1352.
28. Russell RG, Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106.
29. Reszka AA, Rodan GA: Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003; 1: 45-52.
30. Ott S: Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90: 1897-1899.
31. Cunningham J: Bisphosphonates in the renal patient. Nephrol Dial Transplant 2007; 22: 1505-1507.
32. Porras AG, Holland SD, Gertz BJ: Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36: 315-328.
33. Ensrud KE, Barret-Connor EL, Schwartz A, et al: Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 19: 1259-1269.
34. Chevassieux PM, Arlot ME, Reda C, et al: Histomorphometric assessment of the longterm effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475-1480.
35. Eriksen EF, Melsen F, Sod E, et al: Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 31: 620-625.
36. Mashiba T, Turner CH, Hirano T, et al: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524-531.
37. Odvina CV, Zerwekh JE, Rao DS, et al: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301.
38. Kodras K, Haas M: Effect of kidney transplantation on bone. Eur J Clin Invest 2006; 36(suppl 2):63-75.
39. Mitterbauer C, Schwarz C, Haas M, et al: Effects of bisphosphonates on bone loss in the first year after renal transplantation - a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21: 2275-2281.
40. Palmer SC, Strippoli GF, McGregor DO: Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005; 45: 638-649.
41. Coco M, Glicklich D, Faugere MC, et al: Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676.
42. Velasquez-Forero F, Mondragón A, Herrero B, et al: Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 1996; 11(suppl 3): 58-64.
43. Kurz P, Monier-Faugere MC, Bognar B, et al: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861.
44. Moe SM: Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006; 36(suppl 2): 51-62.